C Garcia-Vidal
Overview
Explore the profile of C Garcia-Vidal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
819
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arreba P, Arreba P, Iglesias J, Iglesias J, Rios J, Rios J, et al.
J Hosp Infect
. 2024 Dec;
157:40-44.
PMID: 39701497
Background: The bacterial burden on gel polished (GP) nails, standard polished (SP) nails and unpolished (UP) nails was evaluated before and after hand hygiene (HH) with alcohol-based hand rub. Methods:...
2.
Aiello T, Teijon-Lumbreras C, Gallardo-Pizarro A, Monzo-Gallo P, Martinez-Urrea A, Cuervo G, et al.
Rev Esp Quimioter
. 2024 Oct;
38(1):1-7.
PMID: 39469850
Clinical Decision Support Systems (CDSS) are computer-based tools that leverage the analysis of large volumes of health data to assist healthcare professionals in making clinical decisions, whether preventive, diagnostic, or...
3.
Garcia-Pouton N, Peyrony O, Chumbita M, Aiello F, Monzo P, Gallardo-Pizarro A, et al.
Rev Esp Quimioter
. 2023 Nov;
36 Suppl 1:52-53.
PMID: 37997872
Chimeric antigen receptor (CAR) T cell therapy targeting CD-19 has revolutionized the treatment of refractory B-cell malignancies. However, patients undergoing this therapy face an increased risk of infections due to...
4.
Tellez Santoyo A, Lopera C, Ladino Vasquez A, Segui Fernandez F, Grafia Perez I, Chumbita M, et al.
Rev Esp Quimioter
. 2023 Aug;
36(6):592-596.
PMID: 37575020
Objective: Clinical data on which artificial intelligence (AI) algorithms are trained and tested provide the basis to improve diagnosis or treatment of infectious diseases (ID). We aimed to identify important...
5.
Azanza J, Mensa J, Barberan J, Vazquez L, Perez de Oteyza J, Kwon M, et al.
Rev Esp Quimioter
. 2023 Apr;
36(3):236-258.
PMID: 37017117
The administration of antifungals for therapeutic and, especially, prophylactic purposes is virtually a constant in patients requiring hematology-oncology treatment. Any attempt to prevent or treat Aspergillus or Mucor infections requires...
6.
Herrera S, Torralbo B, Herranz S, Bernal-Maurandi J, Rubio E, Pitart C, et al.
Eur J Clin Microbiol Infect Dis
. 2023 Mar;
42(5):631-638.
PMID: 36964885
Identification of risk factors influencing the duration of carriage of multidrug-resistant Gram-negative bacilli (MDR-GNB) may be useful for infection control. The aim of this study is to estimate the impact...
7.
Retamar-Gentil P, Canton R, Abril Lopez de Medrano V, Barberan J, Canut Blasco A, Duenas Gutierrez C, et al.
Rev Esp Quimioter
. 2022 Dec;
36(1):65-81.
PMID: 36510684
Background: Antibiotic resistance in Gram-negative bacilli poses a serious problem for public health. In hospitals, in addition to high mortality rates, the emergence and spread of resistance to practically all...
8.
Chumbita M, Monzo-Gallo P, Lopera-Marmol C, Aiello T, Puerta-Alcalde P, Garcia-Vidal C
Rev Esp Quimioter
. 2022 Oct;
35 Suppl 3:51-53.
PMID: 36285859
Ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol belong to a novel generation of antibiotics that correspond with the β-lactam family. It is necessary to having new options in treating infections caused by Gram-negative,...
9.
Aiello T, Garcia-Vidal C, Soriano A
Rev Esp Quimioter
. 2022 Oct;
35 Suppl 3:10-15.
PMID: 36285850
The use of antiviral drugs represents an important progress in the therapeutic management of COVID-19, leading to a substantial reduction of SARS-CoV-2-related complications and mortality. In immunocompetent host, peak viral...
10.
Ferrer R, Soriano A, Canton R, Del Pozo J, Garcia-Vidal C, Garnacho-Montero J, et al.
Rev Esp Quimioter
. 2022 Jul;
35(5):455-467.
PMID: 35859521
Objective: Risk factors (RFs) associated with infection progression in patients already colonised by carbapenem-resistant Gram-negative bacteria (CRGNB) have been addressed in few and disperse works. The aim of this study...